# SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma

> **NCT00796731** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 77 (actual)

## Conditions studied

- Lymphoma
- Non-Hodgkin

## Interventions

- **DRUG:** SAR3419

## Key facts

- **NCT ID:** NCT00796731
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2012-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796731, "SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00796731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*